Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 2e-06 |
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 4e-06 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.25 | 7e-05 |
mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.22 | 0.0004 |
mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.2 | 0.0009 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.16 | 0.001 |
mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |